CN114796286A - Application of bacillus coralis in preparation of intestinal tract repair preparation - Google Patents
Application of bacillus coralis in preparation of intestinal tract repair preparation Download PDFInfo
- Publication number
- CN114796286A CN114796286A CN202210430140.7A CN202210430140A CN114796286A CN 114796286 A CN114796286 A CN 114796286A CN 202210430140 A CN202210430140 A CN 202210430140A CN 114796286 A CN114796286 A CN 114796286A
- Authority
- CN
- China
- Prior art keywords
- preparation
- intestinal
- intestinal tract
- repair
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of a bacillus coralis in preparing an intestinal tract repairing agent, wherein the bacillus coralis is a Phascolarcotobacterium faecium strain, and is applied to preparing a probiotic repairing agent for promoting the repair of intestinal flora disorder, a repairing preparation for intestinal tract traumatic injury or a medicine for preventing intestinal tract inflammation; in addition, the invention also discloses an intestinal repair preparation, and the active ingredients of the intestinal repair preparation comprise the strains of the bacillus colatobacter and the bacillus falciparum; the effective viable count of the Phascolarcotobacterium strain is 5 × 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g, in which the strain has a significant intestinal repair effect, preferably further comprising one of a succinic acid-producing probiotic, an edible succinic acid-producing prebiotic and/or a compound of succinic acid and its saltsOne or more combinations, particularly also including Bacteroides thetaiotaomicron bacteria.
Description
Technical Field
The invention belongs to the field of biomedicine, and particularly relates to application of lactobacillus casei in preparation of an intestinal tract repair preparation.
Background
Enteroscopy is an essential item for physical examination of colorectal cancer, and a colorectal cancer (CRC) screening guideline newly issued by MSTF in us 2017: colonoscopy and Fecal Immunochemical Test (FIT) are the cornerstones of various screens, colonoscopy being the first choice. For high risk population, physical examination is the most effective method for early prevention every year; in the current enteroscopy, a large amount of polyethylene glycol (PEG 2000-4000) is used as a cathartic and a lubricant; the use of a large amount of PEG can cause long-term and irreversible damage to intestinal microorganisms, and causes great harm to health.
For the general population, it may appear after enteroscopy treatment: the composition and the homeostasis of intestinal flora are influenced persistently, the flora proportion is changed, and some flora can disappear completely and can be recovered only by external source supplement; intestinal mucosa injury, enteroscopy belong to invasive inspection methods, the intestinal mucosa is easily injured by the biggest harm, and slight lower abdominal pain, abdominal distension, dyspepsia and other symptoms are easily caused after inspection, even intestinal traumatic inflammation is caused. If inflammation or mucosal injury exists in the intestinal tract, bleeding or perforation of the intestinal mucosa can be easily caused, and other complications can be caused.
For patients with a disease focus, intestinal tract mucosa may be damaged after enteroscopy and operation in addition to the harm, so that wounds are caused and the patients are susceptible to infection; displacement of cancer cells.
In conclusion, after enteroscopy, great potential harm exists on human health, and promotion of intestine clearing or enteroscopy intestinal tract repair is necessary for human health guarantee, however, existing research on promotion of enteroscopy intestinal tract repair is few, and no relevant report is found at present.
Disclosure of Invention
In view of the above defects or improvement needs of the prior art, the present invention provides an application of lactobacillus for preparing an intestinal tract repair preparation, and aims to find that a strain of phascolecobacterium faecium specifically promotes repair of traumatic intestinal tract injury, especially rapid repair of intestinal tract after enteroscopy, so as to solve the technical problems that the intestinal tract after enteroscopy is slower in recovery and is easy to cause inflammation or infection.
In order to achieve the above object, according to one aspect of the present invention, there is provided a use of a bacterium belonging to the genus lactobacillus for the preparation of an intestinal tract repair agent, characterized in that the bacterium belonging to the genus lactobacillus is a strain of the bacterium belonging to the genus phascolatobacterium.
Preferably, the application of the corynebacterium in preparing an intestinal tract repairing agent is applied to preparing a probiotic repairing agent for promoting repair of intestinal flora disorder, a preparation for repairing intestinal tract traumatic injury or a medicine for preventing intestinal tract inflammation.
Preferably, the application of the lactobacillus is used for preparing an intestinal tract repair agent, and the lactobacillus is used for preparing a probiotic repair agent for promoting intestinal tract repair after enteroscopy.
Preferably, the application of the corynebacterium in preparing the intestinal repair agent is applied to preparing probiotics for regulating intestinal flora imbalance after enteroscopy and/or preparing probiotics for enhancing intestinal inflammation resistance or relieving intestinal related symptoms; the gut-related symptoms include minor lower abdominal pain, abdominal distension, or weight loss due to dyspepsia.
Preferably, the lactobacillus is used for preparing the intestinal tract repair agent, and the probiotic, the phascolarcotobacterium faecium strain has the effective viable count of 5 multiplied by 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
According to another aspect of the present invention, there is provided an intestinal tract repair preparation, the active ingredient of which comprises a strain of bacillus coelicolor enterobacterium; the effective viable count of the Phascolarcotobacterium faecium strain is 5 × 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
Preferably, the active ingredients of the intestinal tract repair preparation further comprise one or more combinations of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and/or succinic acid and the compound of the salt thereof.
Preferably, the active ingredient of the intestinal tract repair preparation further comprises one or more of succinic acid-producing probiotics or succinic acid.
Preferably, theThe intestinal tract repairing preparation contains Bacteroides thetaiotaomicron as active component and effective viable count of 5 × 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
Preferably, the gut repair formulation is an enteric agent.
In general, compared with the prior art, the above technical solutions contemplated by the present invention can achieve the following beneficial effects due to the discovery that the phascolecyrbacter faecium strain can specifically and rapidly repair intestinal tract after enteroscopy:
the invention discovers that the Phascolatobacterium faecalium strain has the effect of remarkably promoting the repair of intestinal tracts with traumatic injury or flora disturbance of the intestinal tracts, such as remarkably promoting the repair of intestinal tracts after enteroscopy, can be applied to the preparation of a repair agent for the intestinal tracts, and particularly can be applied to the preparation of a probiotic repair agent for the intestinal tracts after enteroscopy, and experimental results show that the Phascolatobacterium faecalium strain has the remarkable effect of promoting the repair of the intestinal tracts after enteroscopy, particularly the effective viable count is 5 multiplied by 10 compared with a control group 9 ～1×10 11 CFU/ml can solve the problems of slow recovery and susceptibility to infection of the intestinal tract after the existing enteroscope, can be used for preparing an intestinal tract repair preparation, and particularly has a synergistic effect when used together with Bacteroides thetaiotaomicron.
In addition, the invention also discovers that the strain can enhance the resistance of the intestinal tract to inflammation, and can be applied to the preparation of medicines for preventing intestinal tract-related inflammation, particularly medicines for preventing intestinal tract inflammation after enteroscopy.
Drawings
FIG. 1 is a comparison of differences in enriched flora between the slow recovery group (left) and the fast recovery group (right)
FIG. 2 shows the change in body weight ratio of mice in the control group and Pf strain group after enteroscopy gut Purge (PEG) and DSS inflammation induction;
FIG. 3 is a graph showing the effect of the gavage Pf strain on the body weight ratio of humanized mouse enteroscopy gut Purge (PEG) and DSS inflammation induction
FIG. 4 is a graph of colon HE staining before (left) and after (right) DSS in control mice (gavage PBS);
FIG. 5 is a graph of humanized mouse DSS (left) pre-and DSS post-colon HE staining;
FIG. 6 is a graph of pre-DSS (left) and post-DSS (right) colon HE staining after gavage of Pf strain in humanized mice;
FIG. 7 is a graph of colitis scores in mice from different treatment groups in a humanized mouse experiment;
FIG. 8 is a comparison of absorbance values of Pf strain under different medium culture conditions; wherein "-sodium succinate" means no sodium succinate in the medium; "+ sodium succinate" indicates sodium succinate in the medium.
FIG. 9 shows the body weight ratio of mice treated with different strains.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Traumatic injury of the intestinal tract easily causes local inflammation of the intestinal tract and even causes intestinal tract and systemic problems. Traumatic injuries include blunt squeezing, friction lacerations, or mechanical injuries of the intestinal mucosa caused by sharp wounds, such as intestinal lacerations caused by eating foreign bodies by mistake, incisions of intestinal related operations, and the like, and particularly, enteroscopy is common.
Enteroscopy is the gold standard for screening colorectal cancer, bowel clearing treatment is required for enteroscopy, and the most obvious change caused by the treatment is that microorganisms in the intestinal tract are cleared, the microecological balance of the intestinal tract is destroyed, a series of intestinal tract problems (such as long-term or irreversible damage of the microorganisms in the intestinal tract, reduction of immunity and the like) can be caused, the destruction cannot be completely recovered in a short period, meanwhile, the recovery capacities of different people are obviously different, and the destroyed intestinal tract environment is easily attacked by inflammation and the like, so that the rapid recovery of the intestinal tract barrier after the enteroscopy is promoted, and the health of the intestinal tract and the resistance to the inflammation are facilitated.
In the traumatic injury of the intestinal tract, because the intestinal mucosa is damaged, the original microecology of the intestinal tract is broken, and particularly, the chemical environment in the intestinal tract is complex and the microecology is difficult to fix the wound surface; even because of the special environment of the wound surface, more serious inflammation or other adverse reactions are caused after the harmful bacteria are planted.
Particularly, in the intestinal microbial flora remodeling process after enteroscopy, how to recover rapidly and in a favorable direction is a key link, the rapid recovery of intestinal microecology is the fastest way by supplementing intestinal microorganisms, and certain key bacteria play a crucial role in intestinal remodeling.
Although intestinal flora has important influence on intestinal health, the number of the microbial flora in the intestinal tract is large, the flora is extremely complex, at least 1000-1150 bacteria exist in the intestinal tract, the environment in the intestinal tract is extremely complex, the colonization effect of exogenous bacteria in the intestinal tract is difficult to determine, and the repair effect of the exogenous bacteria on the intestinal tract after enteroscopy is difficult to guarantee.
Through a large number of experiments, we found that one species of bacillus kohlrabi: the Phascolarcotobacterium faecium strain, Pf for short, can remarkably promote the repair of intestinal tracts after enteroscopy, and can be applied to the preparation of intestinal tract repair agents, particularly probiotics for promoting the repair of intestinal tracts after enteroscopy. Furthermore, the strain is found to be capable of remarkably enhancing the resistance of the intestinal tract to external inflammatory pressure, and can be applied to the preparation of intestinal tract anti-inflammatory products, particularly the preparation of medicines for preventing intestinal tract inflammation, particularly medicines for preventing intestinal tract-related inflammation caused by enteroscopy.
The invention provides an application of lactobacillus in preparing an intestinal tract repairing agent.
The application is applied to the preparation of a probiotic repairing agent for promoting the repair of intestinal flora disturbance caused by mechanical operation of intestinal tracts or the preparation of a medicament for preventing intestinal inflammation, in particular to the preparation of a probiotic repairing agent for promoting the repair of intestinal tracts after enteroscopy, especially the preparation of a probiotic for regulating the imbalance of the intestinal flora after enteroscopy and/or the preparation of a probiotic for relieving intestinal mucosa injury or intestinal related symptoms; the gut-related symptoms include minor lower abdominal pain, abdominal distension, or weight loss due to dyspepsia.
The probiotic repairing agent has effective viable count of Phascolarcotobacterium faecium strain, preferably 5 × 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g, in the concentration range, the bacterial strain has obvious effect of promoting intestinal canal repair.
The probiotic repairing agent preferably further comprises one or more of a succinic acid-producing probiotic, an edible succinic acid-producing prebiotic and/or a compound of succinic acid and a salt thereof; more preferably, the strain comprises one or more of succinic acid-producing probiotics or succinic acid, the succinic acid-producing probiotics or succinic acid can promote the proliferation of the strain and is more beneficial to intestinal tract repair, and in addition, the succinic acid-producing strain is added to be combined with the strain to have a synergistic effect, so that the intestinal tract repair effect is better, for example, Bacteroides thetaiotaomicron, Bt strain for short.
In another aspect, the present invention provides an intestinal tract repair preparation, which comprises as an active ingredient a strain of bacillus coelicolarcinus; the effective viable count of the Phascolarcotobacterium faecium strain is 5 × 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g; preferably, the active ingredients of the composition further comprise one or more of succinic acid-producing probiotics, edible succinic acid-producing prebiotics and/or succinic acid and the compound of the salt thereof; more preferably, the active ingredients further comprise one or more of succinic acid-producing probiotics or succinic acid combination, especially further comprises Bacteroides theonotioomicron, the effective viable count of which is preferably 5X 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
The intestinal tract repair preparation is preferably a pharmaceutically acceptable intestinal solvent.
The following are examples:
example 1 clinical samples changda flora big data analysis
By collecting feces and blood samples of clinical enteroscopy crowds at different periods, carrying out metagenome sequencing and detecting serum immunological indexes, and discovering the phenomenon of inconsistent recovery trend of the intestinal flora of the crowds after the enteroscopy through bioinformatics analysis; analyzing and comparing the intestinal flora of different groups with different recovery speeds through beta diversity analysis, and finding out different strains existing in the intestinal tracts of different groups with different recovery speeds.
The results are shown in FIG. 1, which shows that the abundance of the strain of Coloranium pf is significantly higher in the population with faster recovery than in the population with slower recovery.
Example 2PEG treatment and inflammation-induced intestinal repair Effect of Pf Strain in mouse model
Pf bacteria are Phascolarcotobacterium faecalium JCM 30894 strain in the following examples; DSS is dextran sodium sulfate; the humanized mouse is a mouse for perfusing gastrointestinal tract to repair a slow fecal sample; the Bt bacteria are Bacteroides thetaiotaomicron; HFD is a high fat diet. The strains are purchased from the research center of the engineering technology of the strain of the labor-saving microorganism in Henan province, and the North Na biological detection and detection company Limited in Henan province.
PEG treatment: for each gavage of 200ul, the polyethylene glycol solution contained polyethylene glycol 3350(77.5 g/l), sodium chloride (1.9 g/l), sodium sulfate (7.4 g/l), potassium chloride (0.98 g/l) and sodium bicarbonate (2.2 g/l) diluted in sterile tap water, divided into five equal portions, and taken orally every 30 minutes after 2 hours of fasting. Fecal microbiota transfer was performed 6 hours after the last polyethylene glycol administration.
DSS processing: 2% DSS was formulated and added to the mouse drinking water.
Preparing a bacterial suspension of the Pf strain: fresh bacterial liquid after twice passages is inoculated into a liquid culture medium in an inoculum size of 2% (v/v), and is cultured in an anaerobic constant temperature incubator at 37 ℃ for about 24 hours. Centrifuging at 6000rpm for 10min, washing with sterile physiological saline, resuspending with sterile physiological saline, shaking, mixing, and adjusting the concentration of bacterial suspension to 1 × 10 10 CFU/ml。
Male C57BL/6J mice (SPf grade) 40 at 6 weeks of age, 5 per cage, were housed at a constant temperature of 25. + -. 2 ℃ with a relative humidity of 50. + -. 5% for a diurnal cycle of 12/12 h. After one week of Normal Diet (ND) acclimation, the experimental mice were normally fed during which food intake was recorded weekly and body weights were weighed and randomized into groups. The mice are divided into two groups, 10 mice in each group, 200ul of the probiotic suspension is subjected to intragastric administration after PEG treatment, intragastric administration is carried out once every other day for one week, 5 mice in each group are subjected to DSS treatment after two weeks, the weight change and other inflammation indexes of the mice are monitored, and the body weight ratio change result is shown in figure 2. Wherein, the control group (PBS) is Normal Diet (ND) mice, and the Pf strain group is the perfused Pf probiotic suspension after PEG treatment.
As can be seen from FIG. 2, the body-weight ratio of the control group and Pf strain group at the earlier stage changes steadily and is maintained at about 1, and the two groups have no obvious difference; after DSS treatment, the body weight ratios of mice in a control group and a gavage Pf strain group are reduced, but the control group is obviously reduced, the body weight ratios of the control group and the Pf strain group are very obviously different, and the body weight ratio of the mice in the Pf strain group is obviously larger than that of the control group, so that the body weight reduction degree of the mice is obviously smaller than that of the control group by the gavage Pf strain after DSS treatment, and therefore, the gavage Pf strain is beneficial to promoting the body weight recovery of the mice, probably because the appetite of the mice is improved by the gavage Pf strain, the promotion effect of the Pf strain on intestinal tract repair after enteroscope gut purging is more intuitively seen from the aspect of body weight.
Example 3 intestinal repair Effect of Pf Strain in PEG-treated and inflammation-induced humanized mouse model
In order to simulate the intestinal conditions of human beings more truly, the mice were treated by humanization on the basis of example 1, i.e., they were transplanted with feces for recovering the slow group of human beings, and then were subjected to intestinal clearance treatment (PEG treatment) in clinical enteroscopy, and simultaneously induced to enteritis by DSS, as follows:
antibiotic treatment: the antibiotic solution is prepared by diluting ampicillin, neomycin, metronidazole and vancomycin with sterile water. Ampicillin, neomycin and metronidazole were administered to mice at 200mg/kg and vancomycin at 100mg/kg 1 time a day.
PEG treatment: for each gavage of 200ul, the polyethylene glycol solution contained polyethylene glycol 3350(77.5 g/l), sodium chloride (1.9 g/l), sodium sulfate (7.4 g/l), potassium chloride (0.98 g/l) and sodium bicarbonate (2.2 g/l) diluted in sterile tap water, divided into five equal portions, and taken orally every 30 minutes after 2 hours of fasting. Fecal microbiota transfer was performed 6 hours after the last polyethylene glycol administration.
DSS processing: 2% DSS treatment was carried out for 7 days, with new DSS solution being exchanged every other day.
Preparing a bacterial suspension of the Pf strain: fresh bacterial liquid after twice passages is inoculated into a liquid culture medium in an inoculum size of 2% (v/v), and is cultured in an anaerobic constant temperature incubator at 37 ℃ for about 24 hours. Centrifuging at 6000rpm for 10min, washing with sterile physiological saline, resuspending with sterile physiological saline, shaking, mixing, and adjusting the concentration of bacterial suspension to 1 × 10 10 CFU/ml。
Male C57BL/6J mice (SPf grade) 40 at 6 weeks of age, 5 per cage, were housed at a constant temperature of 25. + -. 2 ℃ with a relative humidity of 50. + -. 5% for a diurnal cycle of 12/12 h. After one week of Normal Diet (ND) acclimation, the experimental mice were fed normal diet, and food intake was recorded weekly, and body weights were weighed and randomly grouped. The mice are divided into two groups, each group comprises 10 mice, the antibiotics treatment is carried out for 8 days, the gastric lavage excrement samples (slow recovery) + 200ul of probiotic suspension are treated by PEG, the gastric lavage is carried out once every other day, the gastric lavage is carried out for one week totally, 5 mice are treated by DSS after two weeks, the weight change and other inflammation indexes of the mice are monitored, the body weight ratio change of the mice is shown in figure 3, colon HE staining before (left) DSS and after (right) DSS is shown in figures 4-6, and the colitis score of the mice is shown in figure 7. Wherein, the control group (PBS) is a Normal Diet (ND) mouse, the humanized mouse group is a mouse group transplanted with a slow recovery group fecal sample, and the Pf strain group is a probiotic suspension of the Pf strain which is treated by the humanized mouse PEG and then perfused with the stomach.
As can be seen from fig. 3, after grouping, DSS treatment is performed on the mice in the control group, the humanized mouse group and the Pf strain group, the body weight ratios of the three groups of mice are reduced, and the body weight ratios of the three groups of mice are significantly different, wherein the body weight ratio of the Pf strain group is greater than that of the control group and that of the humanized mouse group, and the body weight ratio of the Pf strain group is 0.9 after 5 days of DSS treatment, which indicates that the reduction degree of the body weight of the mice in the Pf strain group is very low; and after the humanized mouse group is treated by DSS for 5 days, the body weight ratio is 0.8, which shows that the Pf strain can improve the adverse factor of slow intestinal recovery of the humanized mouse, and further shows that the Pf strain can remarkably promote intestinal repair.
As can be seen from FIGS. 4 to 6, the HE staining patterns of the three groups of colons are significantly different, and as can be seen from FIGS. 4 to 6, after DSS treatment, the mucosal layers of the three groups of colons have different degrees of damage and inflammatory cell infiltration, wherein compared with the control group, the humanized mouse group has significantly weaker tolerance to DSS, severe damage to the colons and significant inflammatory infiltration; compared with a control group, the humanized mouse has stronger tolerance to DSS and reduced colon damage after gavage of the Pf strain, and the Pf strain group in the three groups has the lowest inflammatory cell infiltration degree, so that the resistance of the intestinal tract of the mouse to inflammation after gavage of the Pf strain is obviously better than that of other groups, further, the Pf strain has obvious promotion effect on intestinal tract repair after enteroscope intestinal clearing in the humanized mouse and can obviously enhance the resistance of the intestinal tract to inflammation.
As can be seen from fig. 7, the colitis scores of the mice in each group after DSS treatment were significantly higher than those in the groups without DSS treatment, indicating that the DSS-induced inflammation model was successfully established; after DSS treatment, the colitis score of Pf strain group mice is less than that of a control group mice and less than that of a humanized mouse group mice, wherein the colitis scores of the gavage Pf strain group and the humanized mouse group are obviously different, which indicates that the gavage Pf strain can obviously enhance the resistance of intestinal tract to inflammation, and the Pf strain can obviously improve the symptoms of intestinal tract inflammation.
In conclusion, both the visual observation from the aspect of weight and the HE staining picture of the colon of a mouse and the colon inflammation score show that the gavage Pf strain has obvious promotion effect on intestinal tract repair after enteroscopy gut clearing and can obviously enhance the resistance of the intestinal tract to external inflammation pressure.
Example 4 in vitro growth-promoting experiments with Pf Strain
Medium (-sodium succinate):
tryptone 5g, meat peptone 5g, yeast extract 10g, salt solution 40ml, resazurin (0.1% w/v)0.5ml, Na 2 CO 3 1.0g, 8g of glucose and distilled water, wherein the volume is fixed to 1L, and the pH value is adjusted to 7.0;
salt solution: CaCl 2 2H 2 O 0.25g，MgSO 4 7H 2 O 0.5g，K 2 HPO 4 1.0g，KH 2 PO 4 1.0g，NaHCO 3 10gNaCl 2g and distilled water are added to the solution to make the volume of the solution constant to 1L.
Medium (+ sodium succinate):
tryptone 5g, meat peptone 5g, yeast extract 10g, salt solution 40ml, resazurin (0.1% w/v)0.5ml, Na 2 CO 3 1.0g, 8g of sodium succinate and distilled water, wherein the volume is fixed to 1L, and the pH value is adjusted to 7.0;
salt solution: CaCl 2 2H 2 O 0.25g，MgSO 4 7H 2 O 0.5g，K 2 HPO 4 1.0g，KH 2 PO 4 1.0g，NaHCO 3 10g, NaCl 2g and distilled water are added to the solution to a constant volume of 1L.
The Pf strain was cultured in medium (-sodium succinate) and medium (+ sodium succinate) respectively, and the absorbance values of the strains were as shown in FIG. 8.
From fig. 8, it can be seen that the Pf strain can grow normally in the medium with sodium succinate added thereto, and the Pf strain cannot grow in the medium lacking sodium succinate, indicating that succinic acid or sodium succinate is a necessary carbon source for the growth thereof, and it can be seen that the addition of succinic acid-producing probiotics or edible succinic acid-producing prebiotics or products containing succinic acid and its salts facilitates the growth of the Pf strain in the intestinal tract, indirectly promotes the intestinal repair and may also enhance the intestinal tract's resistance to inflammation.
Therefore, the probiotic agent obtained by compounding the Pf strain with succinic acid-producing probiotics or edible succinic acid-producing prebiotics or one or more of succinic acid and salts thereof has better intestinal tract repair effect.
Example 5 Effect of different Strain treatment on intestinal repair in mice
Experimental groups were as follows: HFD + PEG + PBS (control), HFD + PEG + Pf, HFD + PEG + Pf + Bt
The experimental method comprises the following steps: the procedure was the same as in example 2 except that the mouse diet was High Fat Diet (HFD), and the body weight ratio change of the mice was shown in FIG. 9.
The results of fig. 9 show that the body weight changes of three groups of mice show significant differences, wherein the body weight reduction degrees of the mice are HFD + PEG + PBS, HFD + PEG + Pf, and HFD + PEG + Pf + Bt from top to bottom, and it can be seen that the simultaneous addition of Pf bacteria and Bt bacteria has significant inhibitory effect on the reduction of the body weight of the mice, and the inhibitory effect is superior to that of Pf bacteria alone, which indicates that the combined use of Pf bacteria and Bt bacteria has synergistic effect, and the repair effect on the intestinal tract of the mice is faster and better than that of Pf bacteria alone.
It will be understood by those skilled in the art that the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the invention, and that any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. Use of a bacterium coelicolor in the preparation of an intestinal tract repair agent, wherein the bacterium coelicolor is a strain of Phascolicolor bacteria bacterium.
2. The use of the bacillus coralis strain according to claim 1 in the preparation of an intestinal tract repair agent, wherein the bacillus coralis strain is used in the preparation of a probiotic repair agent for promoting repair of intestinal flora disorders, a preparation for repairing traumatic injury of the intestinal tract, or a medicament for preventing intestinal inflammation.
3. Use of a bacterium of the species Colorado in the preparation of an intestinal repair agent according to claim 2, in the preparation of a probiotic repair agent for promoting intestinal repair after enteroscopy.
4. Use of the bacterium coralber according to claim 1 for the preparation of an intestinal tract repair agent, wherein the bacterium coralber is used for the preparation of a probiotic for regulating intestinal tract flora imbalance after enteroscopy and/or for the preparation of a probiotic for enhancing intestinal tract inflammation resistance or relieving intestinal tract-related symptoms; the gut-related symptoms include minor lower abdominal pain, abdominal distension, or weight loss due to dyspepsia.
5. The use of the bacterium Coomassie according to any one of claims 2 to 4 for the preparation of an intestinal tract repair agent, wherein the probiotic is a Phascolarcotobacterium faecium strain having an effective viable count of 5 x 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
6. An intestinal repair preparation characterized in that the active ingredient comprises a strain of Bacillus colatopsis Phascolatobacterium faecalis; the effective viable count of the Phascolarcotobacterium faecium strain is 5X 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
7. The intestinal tract repair preparation according to claim 6, wherein the active ingredient further comprises one or more combinations of a succinic acid-producing probiotic, an edible succinic acid-producing prebiotic and/or a compound of succinic acid and its salts.
8. The intestinal tract repair preparation according to claim 7, wherein the active ingredient further comprises one or more of a succinic acid-producing probiotic bacterium or a combination of succinic acids.
9. The intestinal tract repair preparation according to claim 8, wherein the active ingredient further comprises bacteriodes theotiotamicron having an effective viable count of 5 x 10 9 ～1×10 11 CFU/ml or 5X 10 9 ～1×10 11 CFU/g。
10. The enteric repair formulation of claim 6 which is an enteric agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210430140.7A CN114796286A (en) | 2022-04-22 | 2022-04-22 | Application of bacillus coralis in preparation of intestinal tract repair preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210430140.7A CN114796286A (en) | 2022-04-22 | 2022-04-22 | Application of bacillus coralis in preparation of intestinal tract repair preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114796286A true CN114796286A (en) | 2022-07-29 |
Family
ID=82505307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210430140.7A Pending CN114796286A (en) | 2022-04-22 | 2022-04-22 | Application of bacillus coralis in preparation of intestinal tract repair preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796286A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013102714A (en) * | 2011-11-11 | 2013-05-30 | Yakult Honsha Co Ltd | New use of bacterium belonging to phascolarctobacterium |
| WO2018189284A1 (en) * | 2017-04-12 | 2018-10-18 | Eth Zurich | Consortia of living bacteria useful for treatment of microbiome dysbiosis |
| CN114146099A (en) * | 2021-12-07 | 2022-03-08 | 美益添生物医药(武汉)有限公司 | FMT donor bacterial liquid containing various low-abundance bacteria and preparation method and application thereof |
-
2022
- 2022-04-22 CN CN202210430140.7A patent/CN114796286A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013102714A (en) * | 2011-11-11 | 2013-05-30 | Yakult Honsha Co Ltd | New use of bacterium belonging to phascolarctobacterium |
| WO2018189284A1 (en) * | 2017-04-12 | 2018-10-18 | Eth Zurich | Consortia of living bacteria useful for treatment of microbiome dysbiosis |
| CN114146099A (en) * | 2021-12-07 | 2022-03-08 | 美益添生物医药(武汉)有限公司 | FMT donor bacterial liquid containing various low-abundance bacteria and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| HIROKO NAGAO-KITAMOTO等: "Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota", NATURE MEDICINE * |
| SEONGHO MA等: "Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model", SCIENTIFIC REPORTS * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
| CN111246839B (en) | New use for the treatment of clostridium difficile infection | |
| CN110169983B (en) | Composite probiotic lactic acid bacteria powder for treating irritable bowel syndrome and application thereof | |
| Osman et al. | Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium | |
| CN1138551C (en) | Eipthelial adhesive lactobacilli | |
| Hagihara et al. | The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue | |
| RU2465320C2 (en) | Composition of lactobacillus strains for preparing therapeutic agent | |
| Kosloske et al. | A bacteriologic basis for the clinical presentations of necrotizing enterocolitis | |
| CN116004483B (en) | Lactococcus garvieae for preventing or treating diarrhea and application thereof | |
| CN114657083A (en) | Lactic acid bacteria fermented milk | |
| Lin et al. | Probiotic/prebiotic correction for adverse effects of iron fortification on intestinal resistance to Salmonella infection in weaning mice | |
| CN110643542A (en) | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof | |
| CN112725219B (en) | Bifidobacterium adolescentis strain and application thereof | |
| JP2022547330A (en) | Compositions and methods for treating autism spectrum disorders | |
| CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
| CN115820498A (en) | Lactobacillus plantarum YJ2406 and application thereof | |
| WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| CN114796286A (en) | Application of bacillus coralis in preparation of intestinal tract repair preparation | |
| WO2021142353A1 (en) | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) | |
| Isozaki et al. | A case of urinary tract infection caused by Kluyvera ascorbata in an infant: case report and review of the literature | |
| Gibson et al. | Recovery of a probiotic organism from human faeces after oral dosing | |
| Liu et al. | Maternal diets have effects on intestinal mucosal flora and susceptibility to colitis of offspring mice during early life | |
| CN116083286B (en) | Bifidobacterium infantis B8762 and application thereof in preparation of probiotic preparation | |
| CN116240151B (en) | Fender-like bacillus and application thereof | |
| CN115433700B (en) | Arthrobacter sakei and application thereof in preparation of medicines for preventing and treating inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |